VolitionRx Limited Releases In-Depth Business Review for 2025 Progress

Volition Issues Business Review 2025

VolitionRx Limited (NYSE AMERICAN: VNRX), a leading global player in the field of epigenetics, recently published its comprehensive Business Review for 2025. This annual review, authored by Group Chief Executive Officer Cameron Reynolds, reflects on a year filled with pivotal achievements and sets the stage for future prospects as the company continues to innovate in the diagnostic arena.

Reflecting on 2025

As we approach the end of 2025, Reynolds conveyed pride in the strides made toward the company's mission: to enhance patient outcomes worldwide through innovative diagnostic solutions. The company's commitment to saving lives through early detection of serious diseases has remained at the forefront of its operations over the past fifteen years.

One of the most notable accomplishments includes the first order for the Nu.Q® Cancer assays, which are now set for clinical certification before being used routinely in lung cancer diagnostics. Additionally, VolitionRx's Nu.Q® NETs assay gained approval for inclusion in a government-supported program in France, directing a significant investment of approximately $7.3 million towards real-world evaluations for early sepsis detection. These advancements signify a major step forward for both cancer and sepsis detection, utilizing cost-effective and user-friendly testing methods.

Transformative Year Ahead

Reynolds confidently anticipates that 2025 will be viewed as transformative for Volition, particularly as the company pivots to prioritize marketing its groundbreaking Nu.Q® platform within the human diagnostics market. A pivotal moment was marked by signing two agreements; one with Werfen for Antiphospholipid Syndrome and another co-marketing agreement with Hologic. Both agreements involve partnerships with multi-billion dollar companies that possess an established global presence in their respective fields.

In addition, VolitionRx has been expanding its intellectual property portfolio, engaging in licensing discussions with numerous leading diagnostic firms worldwide. The company aims to replicate the successful licensing strategy it employed within the veterinary sector for human diagnostics and anticipates the announcement of more agreements throughout 2026.

Progress and Achievements in 2025

Volition made significant strides in sales and revenue, particularly in launching its CE-Marked Nu.Q® NETs automated assay. This innovative product, now evaluated in over 20 hospitals across ten countries, aims to revolutionize routine blood testing through NETosis detection, a crucial element in various diseases beyond sepsis.

Additional commercial triumph was achieved when Volition recorded its first sale of the High Throughput NETs method, facilitating real-time monitoring of neutrophil extracellular traps to assist in therapeutic development targeting ailments like sepsis. Furthermore, an agreement with a prominent pharmaceutical company to utilize Nu.Q® Discover biomarkers is set to accelerate research and drug development across various therapeutic areas, marking a milestone in patient care.

The company's innovation doesn't stop at diagnostics; it has also made strides in the veterinary sector, with the Nu.Q® Vet Cancer Test now establishing itself as the leading canine cancer screening blood test globally.

Scientific Innovations and Developments

Scientific advancements have also been at the core of Volition's 2025 strategy. The introduction of Capture-Seq™, a pioneering method for accurate cancer detection with lower costs, has sparked considerable interest from potential partners eager to license this breakthrough technology.

In addition to technological advancements, a study showcased the innovative lateral flow test for nucleosome quantification—a groundbreaking development that promises to enhance clinical decision-making in point-of-care facilities.

Volition's commitment to research is reinforced by multiple large-scale studies demonstrating the efficacy of its biomarkers in predicting critical patient outcomes in septic cases, particularly regarding the need for renal therapy.

Envisioning the Future

With an optimistic outlook, Volition's goal is to expand the reach of its diagnostic tests significantly, aspiring to license its technology to diverse diagnostic and liquid biopsy companies, ultimately impacting millions of lives globally. By aligning its revolutionary technology with the vast market presence of its partners, Volition envisions achieving its full potential in the healthcare diagnostics sector.

The total addressable markets for Volition's innovative technologies present multi-billion-dollar opportunities not just for the company but for its partners as well. With dedicated efforts toward epigenetic advancements, Volition is set to make continuous strides in revolutionizing disease diagnosis, monitoring, and treatment.

In closing, 2025 has poised VolitionRx Limited for what promises to be a bright and transformative future in the diagnostics landscape, leveraging their innovations to save lives and improve outcomes for countless individuals across the globe.